ClinicaliQ Trial Snapshot
- A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) — Active Not Recruiting • Phase III • NCT04770779.
- Review the linked registry entry for study design, population, endpoints, and operational status.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia. Conditions: Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia Interventions: Placebo Matching Mitapivat, Mitapivat Lead Sponsor: Agios Pharmaceuticals, Inc. Planned Enrollment: 258 participants